Aurobindo 300mg gabapentin capsules

On Nov. 21, 2014, Aurobindo, recalled one lot (GESB14011-A) of **gabapentin capsules, 300mg**, which were distributed in 100-unit bottles under the Northstar label (NDC 16714-0662-01). Empty capsules had been reported in some bottles of the affected lot.

The recalled drugs and lot numbers are below.

**Recalled Drug:** gabapentin capsules, 300mg (Aurobindo, labeled as Northstar)

**NDC Number:** 16714-0662-01

**Recalled Lot Number:** GESB14011-A

**Expiration Date:** December 2015

Aurobindo recommends that:

- Product from the recalled lot should be quarantined.
- Aurobindo Pharma USA’s Pharmacovigilance group at PVG@aurobindousa.com or 732-839-9400, Option 2, should be contacted for more information about the recall.
- Adverse events from the use of prescription drugs should be reported to FDA by visiting www.fda.gov/medwatch or calling 1-800-332-1088.

More information about the recall is at: [http://www.fda.gov/Safety/Recalls/ucm424470.htm](http://www.fda.gov/Safety/Recalls/ucm424470.htm).

**Cubicin® (daptomycin) for Injection**

Cubist Pharmaceuticals has announced the recall of multiple lots of Cubicin® (daptomycin) for injection because vials may contain glass particles. The affected vials are 500mg in 10 mL single-dose (NDC 67919-0011-01).


More information about the recall is at: [http://www.fda.gov/Safety/Recalls/ucm408576.htm](http://www.fda.gov/Safety/Recalls/ucm408576.htm).

Cubist Pharmaceuticals recommends that:

- Recalled product should be quarantined.
Advocate Redi-Code Plus Blood Glucose Test Strips

On June 6, 2014, Diabetic Supply of Suncoast, Inc. recalled all lots of Advocate Redi-Code Plus Blood Glucose Test Strips (NDC – 94046-0001-57). Package labels for the recalled strips do not include the model number (BMB-BA006A). The strips were manufactured by BroadMaster Bio-Tech Corp. for specific blood glucose meters also made by BroadMaster. If the strips are used with similar meters from a different company, blood glucose readings may be inaccurate, potentially leading to serious adverse effects.

Specifics of the recall:

<table>
<thead>
<tr>
<th>Product Description</th>
<th>NDC Number</th>
<th>Lot Number</th>
<th>Expiration Date</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advocate Redi-Code Plus Blood Glucose Test Strips</td>
<td>94046-0001-57</td>
<td>All</td>
<td>All</td>
<td>Diabetic Supply of Suncoast, Inc.</td>
</tr>
</tbody>
</table>

Diabetic Supply of Suncoast, Inc. recommends that:

- Recalled strips should not be used.
- Customers who have recalled strips should contact the company at 561-296-0488 between the hours of 9:00am and 5:00pm ET, Monday through Friday for instructions on how to have recalled product replaced.
- Patients or caregivers of patients who received recalled strips should talk with their prescribers.
- Adverse events from the use of prescription drugs should be reported to FDA by visiting [www.fda.gov/medwatch/report.htm](http://www.fda.gov/medwatch/report.htm) or calling 1-800-FDA-0178.
1% Lidocaine injection 10 mg/mL, 30 mL preservative free single use vials 10% from Hospira Inc. and Cubicin (Daptomycin for injection) 500 mg/10 mL vials from Cubist Pharmaceutical

On April 18, 2014, two products were recalled by their respective manufacturers. There was no impact on members of Community Health Plan of Washington. The recall products are listed below:

<table>
<thead>
<tr>
<th>Product description</th>
<th>NDC number</th>
<th>Lot Number</th>
<th>Expiration Date</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1% Lidocaine injection (10mg/mL) 30mL preservative free single use vials</td>
<td>0409-4279-02</td>
<td>31-427-DK</td>
<td>July 1, 2015</td>
<td>Hospira Inc</td>
</tr>
<tr>
<td>Cubicin (Daptomycin for injection) 500mg/10ml vials</td>
<td>67919-0011-01</td>
<td>280453F</td>
<td>April 2016</td>
<td>Cubist Pharmaceutical</td>
</tr>
</tbody>
</table>

The manufacturers recommend that:

- Patients, caregivers and providers should check supplies of Lidocaine for the recalled lot number. Product from the affected lot should not be used.
- For medical questions about the recall of Lidocaine injection vials, contact Hospira Medical Communications at 1-800-615-0187.
- To arrange for return of recalled Lidocaine product, contact Stericycle at 1-888-835-2723 between the hours of 8 a.m. and 5 p.m. ET, Monday through Friday.
- For questions regarding Cubicin injection, contact Cubist Medical Information at 1.877.282.4786 between the hours of 8 a.m. to 5:30 p.m. EST, Monday through Friday.
- Adverse events from the use of prescription drugs should be reported to FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

Propofol injectable emulsion from Hospira Inc.

On April 2, 2014, Hospira recalled seven lots of Propofol injectable emulsion because glass defects and floating metal particles were observed in reserve vials. Particles in the medication may interfere with administration; particles that enter the patient’s blood
may cause inflammation, capillary occlusion or immune response that could eventually lead to granuloma formation.

The detailed information of the recalled product is listed below:

<table>
<thead>
<tr>
<th>Product description</th>
<th>NDC number</th>
<th>Lot Number</th>
<th>Expiration Date</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propofol Injectable Emulsion</td>
<td>0409-4699-30</td>
<td>29-614-DJ, 29-615-DJ, 29-616-DJ, 29-617-DJ,</td>
<td>May 1, 2015</td>
<td>Hospira Inc</td>
</tr>
<tr>
<td></td>
<td></td>
<td>29-628-DJ, 29-629-DJ, 29-630-DJ</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Our records showed no current utilization of these products by members of CHPW.

The manufacturers recommend that:

- Patients, caregivers and providers should check supplies of Propofol for the recalled lot number. Product from the affected lot should not be used.
- For medical questions about the recall, contact Hospira Medical Communications at 1-800-615-0187
- To arrange for return of recalled product, contact Stericycle at 1-877-272-2158 between the hours of 8 a.m. and 5 p.m. ET, Monday through Friday.
- Adverse events from the use of prescription drugs should be reported to FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

**Effexor XR 150mg and one lot of Greenstone Venlafaxine 150mg extended-release capsules**

On March 6, 2014 Pfizer recalled two lots of Effexor XR 150mg and one lot of Greenstone Venlafaxine 150mg extended-release capsules.

The recalled drugs and lot numbers are listed below:

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Lot number (NDC number)</th>
<th>Manufacturer</th>
<th>Expiration Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effexor XR 150mg capsules</td>
<td>V130142 (NDC 0008-0836-21)</td>
<td>Pfizer</td>
<td>October 2015</td>
</tr>
<tr>
<td>Effexor XR 150mg capsules</td>
<td>V130140 (NDC 0008-0836-22)</td>
<td>Pfizer</td>
<td>October 2015</td>
</tr>
<tr>
<td>Venlafaxine 150mg extended release capsules</td>
<td>V130014 (NDC 59762-0182-02)</td>
<td>Greenstone</td>
<td>August 2015</td>
</tr>
</tbody>
</table>
One bottle of Effexor XR contained a capsule of Tikosyn® (dofetilide), an antiarrhythmic used to convert and maintain normal sinus rhythm for patients with atrial fibrillation and atrial flutter. Taking Tikosyn instead of the antidepressant, venlafaxine, could result in heart rhythm changes that could be serious or possibly life-threatening.

Pfizer recommends that:

- Pharmacists quarantine recalled lots, notify patients who received affected product and arrange returns with Stericycle at 1-888-345-0481 Monday to Friday 8am to 5pm ET.
- Patients with prescriptions from affected lots notify their physicians and return prescriptions to the pharmacies that filled them.
- Questions about the recall may be directed to Pfizer Medical Information at 1-800-438-1985 Monday to Thursday 9am to 8pm ET, Friday 9am to 5pm ET.
- Adverse events from the use of prescription drugs should be reported to FDA by visiting www.fda.gov/medwatch/report.htm or calling 1-800-FDA-0178.